Fed. Circ. Upholds Mylan's PTAB Win On Insulin Drug Lantus
The Federal Circuit on Tuesday invalidated two Sanofi patents on the insulin medication Lantus, upholding decisions from the Patent Trial and Appeal Board that Mylan has called a step forward in...To view the full article, register now.
Already a subscriber? Click here to view full article